Pulmonary Nodules: Stem-Cell Exosome Nebulization Cited for 18-Day Reversal of Inflammatory Lesions

A “pulmonary nodule” on a checkup report often triggers anxiety. With high-resolution CT now common, the source article cites nodule detection in about 20%–40% of routine screening. After a finding, some people worry about malignancy; others live with cough and chest tightness from recurrent inflammation; many are told only to “follow up” with serial scans.

Public reports from Boao Lecheng briefing describes stem-cell exosome nebulization as a regenerative option that does not require systemic infusion and is delivered through the airway. The points below are a digest of that public post—not medical advice. Confirm indication, hospital pathway, and evidence in writing before travel.

Why nodules are common — and what the risks are

The article groups drivers as: long-term haze, kitchen fumes, dust or chemical occupational exposure; fibrotic “scars” after bacterial or viral infection; chronic inflammation and immune imbalance; and a family history of lung tumors that raises incidence and malignant-change risk.

Most nodules are described as benign, yet about 5%–10% are later confirmed malignant. Enlarging benign nodules may still compress lung tissue. The stated principle is early detection and earlier interruption of progression.

Why nebulized delivery is emphasized

Usual care is watchful waiting or systemic antibiotics/steroids—slower, with hepatic and renal burden. Exosomes are described as 30–150 nm vesicles secreted by stem cells, carrying nucleic acids, proteins, and lipids as “repair messengers.”

Nebulization turns the preparation into micron-scale droplets that follow the bronchi to the alveoli, coating lesions with less dilution from the bloodstream. The post also names asthma, refractory pneumonia, pulmonary fibrosis, and ARDS as possible respiratory settings—availability and price must be confirmed with a designated hospital.

Four mechanisms claimed in the source

Anti-inflammatory: down-regulate IL-6 and TNF-α, raise anti-inflammatory mediators—especially for inflammatory nodules. Repair: growth factors on damaged alveolar epithelium and microvascular endothelium. Immune modulation: local microenvironment, less aberrant proliferation. Protection: infection defense, fluid absorption, and sputum clearance.

Clinical observations cited in the post

The article reports reduced inflammatory-nodule burden after nebulization in severe COVID-19 pneumonia without acute allergy or later adverse events, and reversal of some severe inflammatory nodules within about 18 days with cough and tightness resolving.

Case: a 57-year-old man with bilateral solid micronodules plus a right-lung ground-glass nodule; protocol was 15 minutes morning and evening for three weeks. The post says day-90 HRCT showed nodules gone, with only scant old fibrosis in the right middle lobe. It also claims 100% tolerability and little extra-pulmonary drug signal. Treat these as source claims, not a personal prognosis.

If a nodule appears on your scan

The article advises against panic and against delay. Classify the nodule first, then choose follow-up, drugs, surgery, or an investigational path. For cross-border care, verify license, indication, and a written estimate.

The Boao Lecheng International Medical Tourism Pilot Zone, approved by the State Council in February 2013, pilots franchised medical care, oncology, and health management—aiming for “three synchronizations” of technology, equipment, and drugs with international standards.